146 related articles for article (PubMed ID: 32287114)
1. Expression of HER2 and EGFR Proteins in Advanced Stage High-grade Serous Ovarian Tumors Show Mutual Exclusivity.
Crasta J; Ravikumar G; Rajarajan S; Gali S; Kulkarni KA; Vallikad E; Prabhu J
Int J Gynecol Pathol; 2021 Jan; 40(1):49-55. PubMed ID: 32287114
[TBL] [Abstract][Full Text] [Related]
2. Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study.
Erickson BK; Najjar O; Damast S; Blakaj A; Tymon-Rosario J; Shahi M; Santin A; Klein M; Dolan M; Cimino-Mathews A; Buza N; Ferriss JS; Stone RL; Khalifa M; Fader AN
Gynecol Oncol; 2020 Oct; 159(1):17-22. PubMed ID: 32709539
[TBL] [Abstract][Full Text] [Related]
3. The immunoexpression of EGFR, HER2 and HER3 in malignant serous ovarian tumors.
Cîrstea AE; Stepan AE; Mărgăritescu C; Zăvoi RE; Olimid DA; Simionescu CE
Rom J Morphol Embryol; 2017; 58(4):1269-1273. PubMed ID: 29556616
[TBL] [Abstract][Full Text] [Related]
4. Hormone receptor, HER2/NEU and EGFR expression in ovarian carcinoma--is here a prognostic phenotype?
Demir L; Yigit S; Sadullahoglu C; Akyol M; Cokmert S; Kucukzeybek Y; Alacacioglu A; Cakalagaoglu F; Tarhan MO
Asian Pac J Cancer Prev; 2014; 15(22):9739-45. PubMed ID: 25520097
[TBL] [Abstract][Full Text] [Related]
5. Aberrant Expression of Anaplastic Lymphoma Kinase in Ovarian Carcinoma Independent of Gene Rearrangement.
Tang S; Yang F; Du X; Lu Y; Zhang L; Zhou X
Int J Gynecol Pathol; 2016 Jul; 35(4):337-47. PubMed ID: 27271776
[TBL] [Abstract][Full Text] [Related]
6. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
[TBL] [Abstract][Full Text] [Related]
7. Epithelial growth factor receptor status in primary and recurrent ovarian cancer.
Stadlmann S; Gueth U; Reiser U; Diener PA; Zeimet AG; Wight E; Mirlacher M; Sauter G; Mihatsch MJ; Singer G
Mod Pathol; 2006 Apr; 19(4):607-10. PubMed ID: 16554736
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of PD-L1 expression, HER2 amplification, ALK/EML4 fusion, and mismatch repair deficiency as putative predictive and prognostic factors in ovarian carcinoma.
Schmoeckel E; Hofmann S; Fromberger D; Rottmann M; Luthardt B; Burges A; Jeschke U; Kirchner T; Lax SF; Mayr D
Virchows Arch; 2019 May; 474(5):599-608. PubMed ID: 30734108
[TBL] [Abstract][Full Text] [Related]
9. Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma.
Lassus H; Sihto H; Leminen A; Joensuu H; Isola J; Nupponen NN; Butzow R
J Mol Med (Berl); 2006 Aug; 84(8):671-81. PubMed ID: 16607561
[TBL] [Abstract][Full Text] [Related]
10. Alteration in PI3K/mTOR, MAPK pathways and Her2 expression/amplification is more frequent in uterine serous carcinoma than ovarian serous carcinoma.
Mahdi H; Xiu J; Reddy SK; DeBernardo R
J Surg Oncol; 2015 Aug; 112(2):188-94. PubMed ID: 26250968
[TBL] [Abstract][Full Text] [Related]
11. Pattern of HER-2 Gene Amplification and Protein Expression in Benign, Borderline, and Malignant Ovarian Serous and Mucinous Neoplasms.
Mohammed RAA; Makboul R; Elsers DAH; Elsaba TMAM; Thalab AMAB; Shaaban OM
Int J Gynecol Pathol; 2017 Jan; 36(1):50-57. PubMed ID: 27309616
[TBL] [Abstract][Full Text] [Related]
12. Assessment of Her-1, Her-2, And Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma.
Lee CH; Huntsman DG; Cheang MC; Parker RL; Brown L; Hoskins P; Miller D; Gilks CB
Int J Gynecol Pathol; 2005 Apr; 24(2):147-52. PubMed ID: 15782071
[TBL] [Abstract][Full Text] [Related]
13. HER2/ ERBB2 Immunohistochemical Expression and Copy Number Status in Ovarian Mucinous Tumors.
Smithgall MC; Yemelyanova A; Mathew S; Gogineni S; He B; Zhang T; Robinson BD; Tu JJ
Int J Gynecol Pathol; 2024 Mar; 43(2):134-139. PubMed ID: 37406458
[TBL] [Abstract][Full Text] [Related]
14. ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma.
Lassus H; Leminen A; Vayrynen A; Cheng G; Gustafsson JA; Isola J; Butzow R
Gynecol Oncol; 2004 Jan; 92(1):31-9. PubMed ID: 14751135
[TBL] [Abstract][Full Text] [Related]
15. HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations.
Yoshizawa A; Sumiyoshi S; Sonobe M; Kobayashi M; Uehara T; Fujimoto M; Tsuruyama T; Date H; Haga H
Lung Cancer; 2014 Sep; 85(3):373-8. PubMed ID: 25047676
[TBL] [Abstract][Full Text] [Related]
16. HER2 Protein Overexpression and Gene Amplification in Tubo-Ovarian High-grade Serous Carcinomas.
Ersoy E; Cao QJ; Otis CN
Int J Gynecol Pathol; 2022 Jul; 41(4):313-319. PubMed ID: 34320531
[TBL] [Abstract][Full Text] [Related]
17. Expression of HER2/neu, estrogen and progesterone receptors, CA 125 and CA19-9 on cancer cell membrane in patients with serous and mucinous carcinoma of the ovary.
Karaferic A; Jovanovic D; Jelic S
J BUON; 2009; 14(4):635-9. PubMed ID: 20148455
[TBL] [Abstract][Full Text] [Related]
18. HER2 Testing and Reporting in Endometrial Serous Carcinoma: Practical Recommendations for HER2 Immunohistochemistry and Fluorescent In Situ Hybridization: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting.
Buza N
Int J Gynecol Pathol; 2021 Jan; 40(1):17-23. PubMed ID: 33290351
[TBL] [Abstract][Full Text] [Related]
19. Identification of the coexisting HER2 gene amplification and novel mutations in the HER2 protein-overexpressed mucinous epithelial ovarian cancer.
Lin WL; Kuo WH; Chen FL; Lee MY; Ruan A; Tyan YS; Hsu JD; Chiang H; Han CP
Ann Surg Oncol; 2011 Aug; 18(8):2388-94. PubMed ID: 21347793
[TBL] [Abstract][Full Text] [Related]
20. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms.
Wu Y; Soslow RA; Marshall DS; Leitao M; Chen B
Gynecol Oncol; 2004 Dec; 95(3):570-5. PubMed ID: 15581965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
